Hexokinase III
| HK3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | HK3, HKIII, HXK3, hexokinase 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 142570; MGI: 2670962; HomoloGene: 55633; GeneCards: HK3; OMA:HK3 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Hexokinase III, also known as hexokinase C, is an enzyme which in humans is encoded by the Hk3 gene on chromosome 5.[5][6] Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Similar to hexokinases I and II, this allosteric enzyme is inhibited by its product glucose-6-phosphate. [provided by RefSeq, Apr 2009][7]
Structure
[edit]Hexokinase III is one of four homologous hexokinase isoforms in mammalian cells.[8][9][10][11] This protein has a molecular mass of 100 kDa and is composed of two highly similar 50-kDa domains at its N- and C-terminals.[9][10][11][12][13] This high similarity, along with the[clarification needed] and the existence of a 50-kDa hexokinase (Glucokinase, or hexokinase IV), suggests that the 100-kDa hexokinases originated from a 50-kDa precursor via gene duplication and tandem ligation.[13][14][10] As with hexokinase I, only the C-terminal domain possesses catalytic ability, whereas the N-terminal domain is predicted to contain glucose and glucose 6-phosphate binding sites, as well as a 32-residue region essential for proper protein folding.[9][10] Moreover, the catalytic activity depends on the interaction between the two terminal domains.[10] Unlike hexokinase I and hexokinase II, hexokinase III lacks a mitochondrial binding sequence at its N-terminal.[10][15][16]
Function
[edit]As a cytoplasmic isoform of hexokinase and a member of the sugar kinase family, hexokinase III catalyzes the rate-limiting and first obligatory step of glucose metabolism, which is the ATP-dependent phosphorylation of glucose to glucose 6-phosphate.[10][11][17] Physiological levels of glucose 6-phosphate can regulate this process by inhibiting hexokinase III as negative feedback, though inorganic phosphate can relieve glucose 6-phosphate inhibition.[9][13] Inorganic phosphate can also directly regulate hexokinase III, and the double regulation may better suit its anabolic functions.[9] By phosphorylating glucose, hexokinase III effectively prevents glucose from leaving the cell and, thus, commits glucose to energy metabolism.[9][10][12][13] Compared to hexokinase I and hexokinase II, hexokinase III possesses a higher affinity for glucose and will bind the substrate even at physiological levels, though this binding may be attenuated by intracellular ATP.[9] Uniquely, hexokinase III can be inhibited by glucose at high concentrations.[15][14] hexokinase III is also less sensitive to glucose 6-phosphate inhibition.[9][15]
Despite its lack of mitochondrial association, hexokinase III also functions to protect the cell against apoptosis.[10][17] Overexpression of hexokinase III has resulted in increased ATP levels, decreased reactive oxygen species (ROS) production, attenuated reduction in the mitochondrial membrane potential, and enhanced mitochondrial biogenesis. Overall, hexokinase III may promote cell survival by controlling ROS levels and boosting energy production. Currently, only hypoxia is known to induce hexokinase III expression through a HIF-dependent pathway. The inducible expression of hexokinase III indicates its adaptive role in metabolic responses to changes in the cellular environment.[10]
In particular, Hk3 is ubiquitously expressed in tissues, albeit at relatively low abundance.[9][10][13][14] Higher abundance levels have been cited in lung, kidney, and liver tissue.[9][10][15] Within cells, hexokinase III localizes to the cytoplasm and putatively binds the perinuclear envelope.[10][15][16] hexokinase III is the predominant hexokinase in myeloid cells, particularly granulocytes.[18]
Clinical significance
[edit]Hexokinase III is found to be overexpressed in malignant follicular thyroid nodules. In conjunction with cyclin A and galectin-3, hexokinase III could be used as diagnostic biomarker to screen for malignancy in patients.[17][19] Meanwhile, hexokinase III was found to be repressed in acute myeloid leukemia (AML) blast cells and acute promyelocytic leukemia (APL) patients. The transcription factor PU.1 is known to directly activate transcription of the antiapoptotic BCL2A1 gene or inhibit transcription of the p53 tumor suppressor to promote cell survival, and is proposed to also directly activate Hk3 transcription during neutrophil differentiation to support short-term cell survival of mature neutrophils.[16] Regulators repressing hexokinase III expression in AML include PML-RARA and CEBPA.[16][18] Regarding acute lymphoblastic leukemia (ALL), functional enrichment analysis revealed Hk3 as a key gene and suggests that hexokinase III shares antiapoptotic function with HK1 and HK2.[17]
Interactions
[edit]The HK3 promoter is known to interact with PU.1,[16] PML-RARA,[16] and CEBPA.[18]
Interactive pathway map
[edit]Click on genes, proteins and metabolites below to link to respective articles.[§ 1]
- ^ The interactive pathway map can be edited at WikiPathways: "GlycolysisGluconeogenesis_WP534".
See also
[edit]- Hexokinase
- Hexokinase I
- Hexokinase II
- Glucokinase (hexokinase IV)
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000160883 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025877 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Furuta H, Nishi S, Le Beau MM, Fernald AA, Yano H, Bell GI (August 1996). "Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (hexokinase III) to chromosome band 5q35.2 by fluorescence in situ hybridization". Genomics. 36 (1): 206–9. doi:10.1006/geno.1996.0448. PMID 8812439.
- ^ Colosimo A, Calabrese G, Gennarelli M, Ruzzo AM, Sangiuolo F, Magnani M, Palka G, Novelli G, Dallapiccola B (1996). "Assignment of the Hk3 gene (hexokinase III) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization". Cytogenetics and Cell Genetics. 74 (3): 187–8. doi:10.1159/000134409. PMID 8941369.
- ^ "Entrez Gene: hexokinase III hexokinase 3 (white cell)".
- ^ Murakami K, Kanno H, Tancabelic J, Fujii H (2002). "Gene expression and biological significance of hexokinase in erythroid cells". Acta Haematologica. 108 (4): 204–9. doi:10.1159/000065656. PMID 12432216. S2CID 23521290.
- ^ a b c d e f g h i j Okatsu K, Iemura S, Koyano F, Go E, Kimura M, Natsume T, Tanaka K, Matsuda N (November 2012). "Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase". Biochemical and Biophysical Research Communications. 428 (1): 197–202. doi:10.1016/j.bbrc.2012.10.041. PMID 23068103.
- ^ a b c d e f g h i j k l m Wyatt E, Wu R, Rabeh W, Park HW, Ghanefar M, Ardehali H (3 November 2010). "Regulation and cytoprotective role of hexokinase III". PLOS ONE. 5 (11): e13823. Bibcode:2010PLoSO...513823W. doi:10.1371/journal.pone.0013823. PMC 2972215. PMID 21072205.
- ^ a b c Reid S, Masters C (1985). "On the developmental properties and tissue interactions of hexokinase". Mechanisms of Ageing and Development. 31 (2): 197–212. doi:10.1016/s0047-6374(85)80030-0. PMID 4058069. S2CID 40877603.
- ^ a b Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB (Jan 1998). "The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate". Structure. 6 (1): 39–50. doi:10.1016/s0969-2126(98)00006-9. PMID 9493266.
- ^ a b c d e Printz RL, Osawa H, Ardehali H, Koch S, Granner DK (February 1997). "Hexokinase II gene: structure, regulation and promoter organization". Biochemical Society Transactions. 25 (1): 107–12. doi:10.1042/bst0250107. PMID 9056853. S2CID 1851264.
- ^ a b c Cárdenas ML, Cornish-Bowden A, Ureta T (March 1998). "Evolution and regulatory role of the hexokinases". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1401 (3): 242–64. doi:10.1016/s0167-4889(97)00150-x. PMID 9540816.
- ^ a b c d e Lowes W, Walker M, Alberti KG, Agius L (Jan 1998). "Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis". Biochimica et Biophysica Acta (BBA) - General Subjects. 1379 (1): 134–42. doi:10.1016/s0304-4165(97)00092-5. PMID 9468341.
- ^ a b c d e f Federzoni EA, Valk PJ, Torbett BE, Haferlach T, Löwenberg B, Fey MF, Tschan MP (May 2012). "PU.1 is linking the glycolytic enzyme hexokinase III in neutrophil differentiation and survival of APL cells". Blood. 119 (21): 4963–70. doi:10.1182/blood-2011-09-378117. PMC 3367898. PMID 22498738.
- ^ a b c d Gao HY, Luo XG, Chen X, Wang JH (Jan 2015). "Identification of key genes affecting disease free survival time of pediatric acute lymphoblastic leukemia based on bioinformatic analysis". Blood Cells, Molecules & Diseases. 54 (1): 38–43. doi:10.1016/j.bcmd.2014.08.002. PMID 25172542.
- ^ a b c Federzoni EA, Humbert M, Torbett BE, Behre G, Fey MF, Tschan MP (3 March 2014). "CEBPA-dependent hexokinase III and KLF5 expression in primary AML and during AML differentiation". Scientific Reports. 4: 4261. Bibcode:2014NatSR...4E4261F. doi:10.1038/srep04261. PMC 3939455. PMID 24584857.
- ^ Hooft L, van der Veldt AA, Hoekstra OS, Boers M, Molthoff CF, van Diest PJ (February 2008). "Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules". Clinical Endocrinology. 68 (2): 252–7. doi:10.1111/j.1365-2265.2007.03031.x. PMID 17868400. S2CID 25298962.
Further reading
[edit]- Reid S, Masters C (1985). "On the developmental properties and tissue interactions of hexokinase". Mechanisms of Ageing and Development. 31 (2): 197–212. doi:10.1016/S0047-6374(85)80030-0. PMID 4058069. S2CID 40877603.
- Rijksen G, Staal GE, Beks PJ, Streefkerk M, Akkerman JW (December 1982). "Compartmentation of hexokinase in human blood cells. Characterization of soluble and particulate enzymes". Biochimica et Biophysica Acta (BBA) - General Subjects. 719 (3): 431–7. doi:10.1016/0304-4165(82)90230-6. hdl:1874/15535. PMID 7150652. S2CID 24438788.
- Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG (December 2002). "Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry". Molecular & Cellular Proteomics. 1 (12): 947–55. doi:10.1074/mcp.M200066-MCP200. PMID 12543931.
- Palma F, Agostini D, Mason P, Dachà M, Piccoli G, Biagiarelli B, Fiorani M, Stocchi V (February 1996). "Purification and characterization of the carboxyl-domain of human hexokinase type III expressed as fusion protein". Molecular and Cellular Biochemistry. 155 (1): 23–9. doi:10.1007/BF00714329. PMID 8717435. S2CID 6748596.
- Povey S, Corney G, Harris H (May 1975). "Genetically determined polymorphism of a form of hexokinase, HK III, found in human leucocytes". Annals of Human Genetics. 38 (4): 407–15. doi:10.1111/j.1469-1809.1975.tb00630.x. PMID 1190733. S2CID 26343683.
- Anderson NL, Anderson NG (November 2002). "The human plasma proteome: history, character, and diagnostic prospects". Molecular & Cellular Proteomics. 1 (11): 845–67. doi:10.1074/mcp.R200007-MCP200. PMID 12488461.
- He C, Kraft P, Chen C, Buring JE, Paré G, Hankinson SE, Chanock SJ, Ridker PM, Hunter DJ, Chasman DI (June 2009). "Genome-wide association studies identify loci associated with age at menarche and age at natural menopause". Nature Genetics. 41 (6): 724–8. doi:10.1038/ng.385. PMC 2888798. PMID 19448621.
- Fonteyne P, Casneuf V, Pauwels P, Van Damme N, Peeters M, Dierckx R, Van de Wiele C (August 2009). "Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma". Histology and Histopathology. 24 (8): 971–7. PMID 19554504.
- Sui D, Wilson JE (October 2000). "Interaction of insulin-like growth factor binding protein-4, Miz-1, leptin, lipocalin-type prostaglandin D synthase, and granulin precursor with the N-terminal half of type III hexokinase". Archives of Biochemistry and Biophysics. 382 (2): 262–74. doi:10.1006/abbi.2000.2019. PMID 11068878.
- Lowes W, Walker M, Alberti KG, Agius L (Jan 1998). "Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis". Biochimica et Biophysica Acta (BBA) - General Subjects. 1379 (1): 134–42. doi:10.1016/s0304-4165(97)00092-5. PMID 9468341.
- Furuta H, Nishi S, Le Beau MM, Fernald AA, Yano H, Bell GI (August 1996). "Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (hexokinase III) to chromosome band 5q35.2 by fluorescence in situ hybridization". Genomics. 36 (1): 206–9. doi:10.1006/geno.1996.0448. PMID 8812439.
External links
[edit]- Overview of all the structural information available in the PDB for UniProt: P52790 (Hexokinase-3) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.